医学
免疫疗法
佐剂
肝细胞癌
肿瘤科
临床试验
免疫系统
内科学
免疫学
作者
S. Ascari,Rusi Chen,Caterina Vivaldi,Bernardo Stefanini,Andrea De Sinno,Andrea Dalbeni,Piera Federico,Francesco Tovoli
标识
DOI:10.1080/14737140.2025.2461631
摘要
The future of systemic therapies for HCC is likely to be driven by advancements in immunotherapy. Key areas of exploration for the coming years include the discovery of novel checkpoint inhibitors or complementary agents to enhance tumor response when combined with existing treatments, a shift toward neoadjuvant/perioperative trials instead of traditional adjuvant approaches, and the development of personalized neoantigen vaccines.
科研通智能强力驱动
Strongly Powered by AbleSci AI